Christopher L Vandeusen

US Patent:

8202863, Jun 19, 2012

Filed:

Apr 4, 2008

Appl. No.:

12/062641

Inventors:

Suzanne C. Aldous - Gillette NJ, US
John Ziqi Jiang - Hillsborough NJ, US
Jinqi Lu - Somerville NJ, US
Liang Ma - Hillsborough NJ, US
Lan Mu - Bedminster NJ, US
Harry Randall Munson - Annandale NJ, US
Jeffrey Stephen Sabol - Bridgewater NJ, US
Sukanthini Thurairatnam - Bedminster NJ, US
Christopher Loren Vandeusen - East Windsor NJ, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C07D 239/28
C07D 403/12
A61K 31/506

US Classification:

5142358, 51425214, 514256, 544122, 544295, 544296, 544333, 544335

Abstract:

This invention is directed to a compound of formula (I):.

US Patent:

8258130, Sep 4, 2012

Filed:

Sep 30, 2009

Appl. No.:

12/570355

Inventors:

Suzanne C Aldous - Gillette NJ, US
Michael W Fennie - East Stroudsburg PA, US
John Z Jiang - Hillsborough NJ, US
Stanly John - Basking Ridge NJ, US
Lan Mu - Basking Ridge NJ, US
Brian Pedgrift - Flemington NJ, US
James R Pribish - Piscataway NJ, US
Barbara S Rauckman - Flemington NJ, US
Jeffrey S Sabol - Bridgewater NJ, US
Grzegorz T Stoklosa - Hillsborough NJ, US
Sukanthini Thurairatnam - Bedminster NJ, US
Christopher Loren Vandeusen - East Windsor NJ, US

Assignee:

Sanofi - Paris

International Classification:

C07D 239/38
C07D 403/12
A61K 31/506

US Classification:

5142305, 5142358, 514242, 51425214, 514256, 544105, 544122, 544182, 544295, 544296, 544333, 544335

Abstract:

This invention is directed to a compound of formula (I):.

US Patent:

20030032593, Feb 13, 2003

Filed:

Feb 14, 2002

Appl. No.:

10/078247

Inventors:

Paul Wender - Menlo Park CA, US
Jonathan Rothbard - Cupertino CA, US
Lee Wright - Redwood City CA, US
Erik Kreider - Sunnyvale CA, US
Christopher VanDeusen - Columbus OH, US

Assignee:

CellGate, Inc. - Sunnyvale CA

International Classification:

A61K038/16
C12N015/85

US Classification:

514/012000, 435/455000

Abstract:

The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)Z, (ZY)Z, (ZYY)Z and (ZYYY)Z. Subunit “Z” is L-arginine or D-arginine, and subunit “Y” is an amino acid that does not comprise an amidino or guanidino moiety. Subscript “n” is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition.

US Patent:

20030073807, Apr 17, 2003

Filed:

Aug 2, 2002

Appl. No.:

10/211986

Inventors:

Paul Wender - Menlo Park CA, US
Christopher VanDeusen - Mountain View CA, US
Kanaka Pattabiraman - Menlo Park CA, US
Erin Pelkey - Phelps NY, US
Theodore Jessop - Palo Alto CA, US

International Classification:

C07H005/06
C08B037/00

US Classification:

530/317000, 530/324000, 536/018700

Abstract:

Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of -amino groups to the corresponding guanidinyl groups. These compounds find utility as transport agents. Modified oligoguanidine compounds are also described.

US Patent:

20060264608, Nov 23, 2006

Filed:

Mar 14, 2006

Appl. No.:

11/375795

Inventors:

Paul Wender - Menlo Park CA, US
Christopher VanDeusen - East Windsor NJ, US
Kanaka Pattabiraman - Palo Alto CA, US
Erin Pelkey - Phelps NY, US
Theodore Jessop - Princeton NJ, US

International Classification:

C07K 7/08
C07K 7/06

US Classification:

530326000, 530327000, 530328000, 530329000, 530330000

Abstract:

Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of ω-amino groups to the corresponding guanidinyl groups. These compounds find utility as transport agents. Modified oligoguanidine compounds are also described.

US Patent:

20100081618, Apr 1, 2010

Filed:

Sep 3, 2009

Appl. No.:

12/553649

Inventors:

Paul A. Wender - Menlo Park CA, US
Jonathan B. Rothbard - Cupertino CA, US
Lee Wright - Redwood City CA, US
Erik L. Kreider - Sunnyvale CA, US
Christopher L. VanDeusen - Columbus OH, US

International Classification:

A61K 38/16
A61K 38/10
A61K 38/08
A61P 43/00

US Classification:

514 12, 514 17, 514 16, 514 15, 514 14, 514 13

Abstract:

The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)Z, (ZY)Z, (ZYY)Z and (ZYYY)Z. Subunit “Z” is L-arginine or D-arginine, and subunit “Y” is an amino acid that does not comprise an amidino or guanidino moiety. Subscript “n” is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition.

US Patent:

20120190695, Jul 26, 2012

Filed:

Apr 4, 2012

Appl. No.:

13/439511

Inventors:

Christopher L. VANDEUSEN - East Windsor NJ, US
Franz J. WEIBERTH - Ringoes NJ, US
Harpal S. GILL - Lambertville NJ, US
George LEE - Somerville NJ, US
Andrea HILLEGASS - Nazareth PA, US

Assignee:

SANOFI - Paris

International Classification:

A61K 31/506
A61P 37/08
A61P 29/00
A61P 11/06
A61P 27/02
A61P 11/00
C07C 259/18
C07D 271/06
C07D 401/14
C07D 413/14
A61P 11/02

US Classification:

514256, 544333, 564229, 548131

Abstract:

This invention is directed to a compound of formula (I):wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).

US Patent:

20200347042, Nov 5, 2020

Filed:

May 20, 2020

Appl. No.:

16/878842

Inventors:

- Cambridge MA, US
Andrés GAGETE MATEOS - Valencia, ES
Peter J. MACHIN - Streatham, GB
Christopher Loren VANDEUSEN - Hopkinton MA, US

International Classification:

C07D 413/06
C07D 311/22
A61P 37/02
C07D 405/14
C07D 413/14
C07D 405/06
A61P 35/00
C07D 405/12
A61P 37/00
A61P 17/00
A61P 11/06
C07D 413/12
A61P 29/00
C07D 311/58
A61P 3/10

Abstract:

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.